CO5611161A2 - Tratar desorden inmunologico usando agonistas de interleucina-21/receptor de interleucina-21 - Google Patents
Tratar desorden inmunologico usando agonistas de interleucina-21/receptor de interleucina-21Info
- Publication number
- CO5611161A2 CO5611161A2 CO05095726A CO05095726A CO5611161A2 CO 5611161 A2 CO5611161 A2 CO 5611161A2 CO 05095726 A CO05095726 A CO 05095726A CO 05095726 A CO05095726 A CO 05095726A CO 5611161 A2 CO5611161 A2 CO 5611161A2
- Authority
- CO
- Colombia
- Prior art keywords
- agonist
- interleucine
- antibody
- polypeptide
- agonists
- Prior art date
Links
- 208000026278 immune system disease Diseases 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 9
- 108010074108 interleukin-21 Proteins 0.000 abstract 9
- 238000000034 method Methods 0.000 abstract 9
- 102100030704 Interleukin-21 Human genes 0.000 abstract 5
- 230000001270 agonistic effect Effects 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 2
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 abstract 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 2
- 229960002930 sirolimus Drugs 0.000 abstract 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 abstract 1
- 102000008640 interleukin-21 receptor activity proteins Human genes 0.000 abstract 1
- 108040002099 interleukin-21 receptor activity proteins Proteins 0.000 abstract 1
- 229960000681 leflunomide Drugs 0.000 abstract 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 abstract 1
- 229960000485 methotrexate Drugs 0.000 abstract 1
- 229960000235 temsirolimus Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45692003P | 2003-03-21 | 2003-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5611161A2 true CO5611161A2 (es) | 2006-02-28 |
Family
ID=33098171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05095726A CO5611161A2 (es) | 2003-03-21 | 2005-09-21 | Tratar desorden inmunologico usando agonistas de interleucina-21/receptor de interleucina-21 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20060159655A1 (https=) |
| EP (1) | EP1608315A4 (https=) |
| JP (1) | JP2006523682A (https=) |
| KR (1) | KR20060015482A (https=) |
| CN (1) | CN1849131A (https=) |
| AU (1) | AU2004224277A1 (https=) |
| BR (1) | BRPI0408523A (https=) |
| CA (1) | CA2518854A1 (https=) |
| CO (1) | CO5611161A2 (https=) |
| CR (1) | CR7994A (https=) |
| EC (1) | ECSP056027A (https=) |
| IL (1) | IL198102A0 (https=) |
| MX (1) | MXPA05010035A (https=) |
| NO (1) | NO20054343L (https=) |
| RU (1) | RU2005132458A (https=) |
| WO (1) | WO2004084835A2 (https=) |
| ZA (1) | ZA200507235B (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057128A (en) | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| US7314623B2 (en) * | 2002-07-15 | 2008-01-01 | Wyeth | Methods and compositions for modulating T helper (Th) cell development and function |
| NZ542306A (en) | 2003-03-14 | 2008-04-30 | Wyeth Corp | Antibodies against human IL-21 receptor and uses therefor |
| EP1670501A2 (en) * | 2003-09-25 | 2006-06-21 | ZymoGenetics, Inc. | Methods of treating autoimmune diseases using il-21 |
| US20060228331A1 (en) | 2003-10-10 | 2006-10-12 | Novo Nordisk A/S | IL-21 Derivatives and variants |
| EP1753458A4 (en) * | 2004-05-19 | 2009-07-22 | Wyeth Corp | MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS |
| RU2007102287A (ru) * | 2004-08-05 | 2008-09-10 | Вайет (Us) | Антагонисты активности рецептора интерлейкина-21 |
| GT200600148A (es) | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| CA2604222A1 (en) * | 2005-04-18 | 2006-10-26 | Novo Nordisk A/S | Il-21 variants |
| WO2007111714A2 (en) * | 2005-11-28 | 2007-10-04 | Zymogenetics, Inc. | Il-21 antagonists |
| WO2007114861A2 (en) * | 2005-11-28 | 2007-10-11 | Zymogenetics, Inc. | Il-21 receptor antagonists |
| US7883700B2 (en) | 2007-12-07 | 2011-02-08 | Zymogenetics, Inc. | Anti-human IL-21 monoclonal antibodies |
| WO2009100035A2 (en) * | 2008-02-01 | 2009-08-13 | Wyeth | Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3) |
| PE20100141A1 (es) * | 2008-05-23 | 2010-02-22 | Wyeth Corp | Proteina de union al receptor de interleuquina 21 |
| US8178097B2 (en) * | 2008-05-23 | 2012-05-15 | Wyeth Llc | Methods of treatment utilizing binding proteins of the interleukin-21 receptor |
| US20100075329A1 (en) * | 2008-09-23 | 2010-03-25 | O'toole Margot | Methods for predicting production of activating signals by cross-linked binding proteins |
| CA2740077A1 (en) * | 2008-10-08 | 2010-04-15 | Cambridge Enterprise Limited | Methods and compositions for diagnosis and treatment |
| CA2798739A1 (en) * | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| EP2665486B1 (en) | 2011-01-18 | 2019-12-25 | Bioniz, LLC | Compositions for modulating gamma-c-cytokine activity |
| EP3502236B1 (en) * | 2011-02-18 | 2023-08-23 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
| US9959384B2 (en) | 2013-12-10 | 2018-05-01 | Bioniz, Llc | Methods of developing selective peptide antagonists |
| WO2017062685A1 (en) | 2015-10-09 | 2017-04-13 | Bioniz, Llc | Modulating gamma - c -cytokine activity |
| AU2016341529B2 (en) | 2015-10-22 | 2023-03-30 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
| US12600757B2 (en) | 2017-04-07 | 2026-04-14 | Bioniz Therapeutics, Inc. | Peptides inhibiting gamma-c-cytokine activity and methods of use |
| KR102454376B1 (ko) * | 2018-07-04 | 2022-10-17 | 서울대학교산학협력단 | 신경손상의 면역세포치료 |
| CN120365435A (zh) | 2018-08-30 | 2025-07-25 | 免疫生物公司 | 单链嵌合多肽和多链嵌合多肽以及其用途 |
| EP3843788A1 (en) | 2018-08-30 | 2021-07-07 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| CN112996805A (zh) | 2018-08-30 | 2021-06-18 | Hcw生物科技公司 | 多链嵌合多肽和其用途 |
| CA3137971A1 (en) | 2019-05-03 | 2020-11-12 | Bioniz, Llc | Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders |
| JP7713393B2 (ja) | 2019-06-21 | 2025-07-25 | イミュニティーバイオ インコーポレイテッド | 多鎖キメラポリペプチドおよびその使用 |
| EP4103599A1 (en) | 2020-02-11 | 2022-12-21 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| US12115191B2 (en) | 2020-02-11 | 2024-10-15 | Immunitybio, Inc. | Methods of treating age-related and inflammatory diseases |
| KR20220140535A (ko) | 2020-02-11 | 2022-10-18 | 에이치씨더블유 바이올로직스, 인크. | 크로마토그래피 수지 및 이의 용도 |
| EP4143231A1 (en) | 2020-04-29 | 2023-03-08 | HCW Biologics, Inc. | Anti-cd26 proteins and uses thereof |
| EP4146669A4 (en) * | 2020-05-08 | 2024-06-05 | Alastin Skincare, Inc. | Compositions and methods for modulating inflammation and wound healing |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| EP4157460A1 (en) | 2020-06-01 | 2023-04-05 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
| EP4507711A1 (en) | 2022-04-13 | 2025-02-19 | ImmunityBio, Inc. | Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder |
| CN120813605A (zh) * | 2023-01-06 | 2025-10-17 | 泰温治疗私人有限公司 | 抗原结合分子 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010025022A1 (en) * | 1997-11-26 | 2001-09-27 | Kikly Kristine Kay | Hnovilr |
| US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| US7189400B2 (en) * | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
| US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| EP1082433A4 (en) * | 1998-05-29 | 2003-01-02 | Human Genome Sciences Inc | Interleukins 21 and 22 |
| AU5104799A (en) * | 1998-08-04 | 2000-02-28 | Regeneron Pharmaceuticals, Inc. | Novel orphan cytokine receptors |
| US6576744B1 (en) * | 1998-09-23 | 2003-06-10 | Zymogenetics, Inc. | Cytokine receptor zalpha11 |
| US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| US20020090680A1 (en) * | 1999-05-18 | 2002-07-11 | Millennium Pharmaceuticals, Inc. | Novel IL-9/IL-2 receptor-like molecules and uses thereof |
| ES2279809T3 (es) * | 2000-04-05 | 2007-09-01 | Zymogenetics, Inc. | Receptores de citoquina zalfa11 solubles. |
| ES2629395T3 (es) * | 2001-10-04 | 2017-08-09 | Genetics Institute, Llc | Métodos y composiciones para modular la actividad de la interleucina-21 |
| ES2334338T3 (es) * | 2001-11-05 | 2010-03-09 | Zymogenetics, Inc. | Antagonistas de il-21. |
| CA2481304A1 (en) * | 2002-03-27 | 2003-10-09 | Patrick Hwu | Method for treating cancer in humans |
| US20040016010A1 (en) * | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
| DK1531850T3 (da) * | 2002-06-07 | 2012-06-04 | Zymogenetics Inc | Anvendelse af 1L-21 og monoklonalt antistof til behandling af solide cancere |
| US7314623B2 (en) * | 2002-07-15 | 2008-01-01 | Wyeth | Methods and compositions for modulating T helper (Th) cell development and function |
| NZ542306A (en) * | 2003-03-14 | 2008-04-30 | Wyeth Corp | Antibodies against human IL-21 receptor and uses therefor |
| EP1753458A4 (en) * | 2004-05-19 | 2009-07-22 | Wyeth Corp | MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS |
| RU2007102287A (ru) * | 2004-08-05 | 2008-09-10 | Вайет (Us) | Антагонисты активности рецептора интерлейкина-21 |
| US7533965B2 (en) * | 2005-03-07 | 2009-05-19 | Eastman Kodak Company | Apparatus and method for electrostatically charging fluid drops |
| GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis |
-
2004
- 2004-03-22 CA CA002518854A patent/CA2518854A1/en not_active Abandoned
- 2004-03-22 CN CNA2004800076306A patent/CN1849131A/zh active Pending
- 2004-03-22 MX MXPA05010035A patent/MXPA05010035A/es unknown
- 2004-03-22 EP EP04758055A patent/EP1608315A4/en not_active Withdrawn
- 2004-03-22 ZA ZA200507235A patent/ZA200507235B/en unknown
- 2004-03-22 RU RU2005132458/13A patent/RU2005132458A/ru unknown
- 2004-03-22 BR BRPI0408523-0A patent/BRPI0408523A/pt not_active IP Right Cessation
- 2004-03-22 KR KR1020057017652A patent/KR20060015482A/ko not_active Withdrawn
- 2004-03-22 AU AU2004224277A patent/AU2004224277A1/en not_active Abandoned
- 2004-03-22 WO PCT/US2004/008833 patent/WO2004084835A2/en not_active Ceased
- 2004-03-22 US US10/806,611 patent/US20060159655A1/en not_active Abandoned
- 2004-03-22 JP JP2006507478A patent/JP2006523682A/ja active Pending
-
2005
- 2005-09-16 CR CR7994A patent/CR7994A/es not_active Application Discontinuation
- 2005-09-20 EC EC2005006027A patent/ECSP056027A/es unknown
- 2005-09-20 NO NO20054343A patent/NO20054343L/no not_active Application Discontinuation
- 2005-09-21 CO CO05095726A patent/CO5611161A2/es unknown
-
2009
- 2009-04-07 IL IL198102A patent/IL198102A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004084835A3 (en) | 2006-05-26 |
| IL198102A0 (en) | 2009-12-24 |
| US20060159655A1 (en) | 2006-07-20 |
| WO2004084835A2 (en) | 2004-10-07 |
| CA2518854A1 (en) | 2004-10-07 |
| RU2005132458A (ru) | 2006-03-20 |
| KR20060015482A (ko) | 2006-02-17 |
| BRPI0408523A (pt) | 2006-03-21 |
| EP1608315A2 (en) | 2005-12-28 |
| ECSP056027A (es) | 2006-09-18 |
| MXPA05010035A (es) | 2005-11-17 |
| AU2004224277A1 (en) | 2004-10-07 |
| CN1849131A (zh) | 2006-10-18 |
| ZA200507235B (en) | 2007-03-28 |
| NO20054343L (no) | 2005-11-24 |
| EP1608315A4 (en) | 2008-07-16 |
| JP2006523682A (ja) | 2006-10-19 |
| CR7994A (es) | 2006-10-17 |
| NO20054343D0 (no) | 2005-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5611161A2 (es) | Tratar desorden inmunologico usando agonistas de interleucina-21/receptor de interleucina-21 | |
| EP2056838B1 (en) | Combination therapy for treatment of immune disorders | |
| Okiyama et al. | Therapeutic effects of interleukin‐6 blockade in a murine model of polymyositis that does not require interleukin‐17A | |
| RU2192281C2 (ru) | Способы и композиции для иммуномодуляции | |
| RU2421464C2 (ru) | Человеческие антитела к il-13 и их терапевтическое применение | |
| JP2006523682A5 (https=) | ||
| JP6920207B2 (ja) | シンデカン−２のモジュレーターとその使用 | |
| RU2015114923A (ru) | СПОСОБЫ ЛЕЧЕНИЯ IL-1β-ЗАВИСИМЫХ ЗАБОЛЕВАНИЙ | |
| US20110002928A1 (en) | Uses of Mammalian Cytokine; Related Reagents | |
| WO2004071517A2 (en) | Uses of il-23 related reagents | |
| ATE283289T1 (de) | Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten | |
| HRP20110334T1 (hr) | PROTUTIJELA SPECIFIČNA ZA TGF-ß1 | |
| JP2013139478A (ja) | インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法 | |
| AU2005291741B2 (en) | Type I interferon blocking agents for prevention and treatment of psoriasis | |
| CN101466735A (zh) | 多发性硬化和/或类风湿性关节炎的治疗 | |
| TW201043961A (en) | Methods for monitoring the efficacy of anti-IL-2R antibodies in multiple sclerosis patients | |
| Hohlfeldf | Therapeutic strategies in multiple sclerosis. I. Immunotherapy | |
| KR20210042138A (ko) | 건선 치료 방법 | |
| Bahner et al. | Interferon-beta-1b increases serum interleukin-12 p40 levels in primary progressive multiple sclerosis patients | |
| JP2019519470A5 (https=) | ||
| AU2014200946A1 (en) | Combination therapy for treatment of immune disorders | |
| PL448731A1 (pl) | Przeciwciała bispecyficzne anty–IL-17A i anty-IL-6 oraz ich zastosowanie w terapii, zwłaszcza w leczeniu chorób immunologicznych | |
| CN118251413A (zh) | 用抗il23特异性抗体治疗克罗恩病的方法 | |
| HK1051965A1 (en) | Use of il-18 inhibitors | |
| HK1051965B (en) | Use of il-18 inhibitors |